Repare Therapeutics (RPTX) News Today → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free RPTX Stock Alerts $3.70 +0.20 (+5.71%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 12 at 9:47 AM | finance.yahoo.comNeed To Know: Analysts Are Much More Bullish On Repare Therapeutics Inc. (NASDAQ:RPTX)May 11 at 6:45 PM | morningstar.comRepare Therapeutics Inc Ordinary SharesMay 9, 2024 | finance.yahoo.comRepare Therapeutics First Quarter 2024 Earnings: Beats ExpectationsMay 8, 2024 | finanznachrichten.deRepare Therapeutics Inc.: Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial ResultsMay 8, 2024 | marketwatch.comRepare Therapeutics Shares Rise 17% After 1Q Earnings, Revenue BeatsMay 8, 2024 | theglobeandmail.comSmall Cap Massively Bid Following Key Q1 Earnings BeatMay 7, 2024 | businesswire.comRepare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial ResultsApril 30, 2024 | businesswire.comDebiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 InhibitionApril 30, 2024 | businesswire.comRepare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 InhibitionApril 28, 2024 | investing.comRepare Therapeutics appoints new board memberApril 26, 2024 | finance.yahoo.comRepare Therapeutics Appoints Steven H. Stein, M.D. to its Board of DirectorsApril 26, 2024 | businesswire.comRepare Therapeutics Appoints Steven H. Stein, M.D.April 22, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Repare Therapeutics on Strong Clinical Outlook and Attractive ValuationApril 20, 2024 | finance.yahoo.comRepare Therapeutics Inc.'s (NASDAQ:RPTX) market cap dropped US$21m last week; Private equity firms bore the bruntApril 20, 2024 | marketbeat.comRepare Therapeutics (NASDAQ:RPTX) Rating Increased to Buy at Bloom BurtonBloom Burton upgraded Repare Therapeutics from an "accumulate" rating to a "buy" rating in a research report on Friday.April 2, 2024 | insidertrades.comLloyd Mitchell Segal Sells 2,491 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) StockMarch 29, 2024 | investing.comRepare therapeutics exec sells shares worth $7,000March 28, 2024 | insidertrades.comInsider Selling: Repare Therapeutics Inc. (NASDAQ:RPTX) CEO Sells 2,650 Shares of StockMarch 28, 2024 | insidertrades.comRepare Therapeutics Inc. (NASDAQ:RPTX) CEO Sells $12,693.50 in StockMarch 16, 2024 | finance.yahoo.comRPTX Apr 2024 7.500 callMarch 16, 2024 | finance.yahoo.comRPTX Jul 2024 7.500 callMarch 15, 2024 | businesswire.comRepare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsMarch 11, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTXMarch 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Repare Therapeutics: Strong Financials and Promising Clinical Catalysts AheadMarch 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTXMarch 1, 2024 | finance.yahoo.comRepare Therapeutics Full Year 2023 Earnings: Misses ExpectationsFebruary 29, 2024 | businesswire.comRepare Therapeutics to Participate in Two Upcoming Investor ConferencesFebruary 28, 2024 | msn.comSHAREHOLDER ALERT: Potential Recovery for Repare Therapeutics Inc. (RPTX) InvestorsFebruary 28, 2024 | benzinga.comRecap: Repare Therapeutics Q4 EarningsFebruary 28, 2024 | finance.yahoo.comRepare Therapeutics Inc (RPTX) Reports Financial Outcomes for Q4 and Full Year 2023February 28, 2024 | businesswire.comRepare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 24, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTXFebruary 22, 2024 | markets.businessinsider.comStrong Buy: Repare Therapeutics’ Promising Clinical Outcomes in Cancer TherapyFebruary 17, 2024 | finance.yahoo.comWe're Keeping An Eye On Repare Therapeutics' (NASDAQ:RPTX) Cash Burn RateFebruary 17, 2024 | finance.yahoo.comRPTX Mar 2024 7.500 callFebruary 16, 2024 | businesswire.comKirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)February 16, 2024 | businesswire.comKirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)February 16, 2024 | marketbeat.comRepare Therapeutics Inc. (NASDAQ:RPTX) to Post Q2 2024 Earnings of ($0.96) Per Share, HC Wainwright ForecastsRepare Therapeutics Inc. (NASDAQ:RPTX - Free Report) - Analysts at HC Wainwright dropped their Q2 2024 EPS estimates for Repare Therapeutics in a research report issued on Wednesday, February 14th. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.96) per shareFebruary 15, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTXFebruary 15, 2024 | finance.yahoo.comRepare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664February 15, 2024 | marketbeat.comBloom Burton Downgrades Repare Therapeutics (NASDAQ:RPTX) to AccumulateBloom Burton lowered shares of Repare Therapeutics from a "buy" rating to an "accumulate" rating in a research note on Tuesday.February 15, 2024 | marketbeat.comFY2023 EPS Estimates for Repare Therapeutics Inc. (NASDAQ:RPTX) Cut by AnalystRepare Therapeutics Inc. (NASDAQ:RPTX - Free Report) - Investment analysts at Capital One Financial cut their FY2023 earnings estimates for shares of Repare Therapeutics in a research report issued on Monday, February 12th. Capital One Financial analyst T. Chiang now forecasts that the company wiFebruary 15, 2024 | businesswire.comRepare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664February 15, 2024 | investing.comRepare Therapeutics Inc (RPTX)February 15, 2024 | finance.yahoo.comEBS Sep 2024 7.500 putFebruary 15, 2024 | finance.yahoo.comEBS Jun 2024 1.000 putFebruary 14, 2024 | marketbeat.comHC Wainwright Lowers Repare Therapeutics (NASDAQ:RPTX) Price Target to $10.00HC Wainwright cut their price target on shares of Repare Therapeutics from $25.00 to $10.00 and set a "buy" rating on the stock in a research note on Wednesday.February 13, 2024 | msn.comRoche Terminates Cancer Drug Pact With Repare Therapeutics, Its Second Walkout Within A MonthFebruary 13, 2024 | markets.businessinsider.comBuy Rating on Repare Therapeutics: Solid Financials and Promising Oncology Pipeline Despite Roche SetbackFebruary 13, 2024 | finance.yahoo.comRepare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock? Get Repare Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. RPTX Media Mentions By Week RPTX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RPTX News Sentiment▼0.710.57▲Average Medical News Sentiment RPTX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RPTX Articles This Week▼92▲RPTX Articles Average Week Get Repare Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RPTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: DiaMedica Therapeutics News PDS Biotechnology News Sagimet Biosciences News Syros Pharmaceuticals News FibroGen News Adicet Bio News Amylyx Pharmaceuticals News Regulus Therapeutics News Nuvectis Pharma News InterCure News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RPTX) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repare Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
